Module 1 · Knowledge Layer

Literature Intelligence

Understand everything published. Enter one entity — receive one structured intelligence report instead of 1,000 PDFs.

2.41M papers indexed

ENTITY: Oral CancerEGCGNrf2Green Tea+ add

Export report Ask follow-up

Knowledge Objects–on "Oral Cancer"

Evidence strength (avg)–study-design weighted

Extraction confidence (avg)–parser certainty

Contradictions2flagged by engine

Structured evidence — Oral Cancer

OSCC arises from tobacco/areca-nut carcinogenesis compounded by chronic inflammation and oxidative stress. The literature converges on NF-κB, STAT3, Nrf2/KEAP1 and EGFR as central druggable nodes. Phytochemical chemoprevention evidence is strongest for polyphenols and flavonoids, with reproducible apoptosis and tumour-burden reduction in cell and animal models.

Bottom line: Pre-clinical case is strong; clinical validation and delivery optimisation are the rate-limiting steps.

Evidence by model

Cell studies

1,240 · consistent across SCC-9, CAL-27, SCC-25

Animal studies

318 · DMBA hamster pouch dominant

Clinical studies

27 · small, heterogeneous

Cluster A · 38%

Polyphenol chemoprevention

EGCG, curcumin, resveratrol · antioxidant & anti-inflammatory mechanisms.

Cluster B · 27%

Signalling & targets

NF-κB / STAT3 / Nrf2 mechanistic dissection.

Cluster C · 19%

Delivery systems

Nanoemulsion, oral films, exosomes.

Cluster D · 10%

Clinical trials

Small-cohort chemoprevention studies.

Cluster E · 6%

Biomarkers

8-OHdG, Ki-67, p53 status.

Extracted claim	Model	Effect
EGCG induces apoptosis via caspase-3/9 in OSCC lines	In-vitro	↑ apoptosis
EGCG upregulates Nrf2/HO-1 cytoprotective axis	In-vitro	↑ Nrf2
Nimbolide suppresses NF-κB nuclear translocation	In-vivo	↓ NF-κB
Curcumin plasma levels sub-therapeutic orally	Clinical	↓ bioavail.

Contradiction 1 — Curcumin efficacy: Strong pre-clinical tumour suppression vs 2 RCTs showing sub-therapeutic oral plasma levels. Resolution: delivery-system dependent.

Contradiction 2 — Nrf2 role: Cytoprotective in chemoprevention vs pro-survival in established tumours. Resolution: stage/context dependent.

Contradiction 3 — EGCG dosing: Hormetic — low doses antioxidant, high doses pro-oxidant. Resolution: dose-window matters.

Highly-cited hub (gold) anchors the EGCG-OSCC literature; recent nodes (teal) branch into delivery and combination work.

Ferroptosis in OSCC ▲Nano-EGCG ▲Combination botanicals ▲ Exosome deliveryAhR ligandsGut–oral axis

Topics sized by 3-year citation acceleration. Green = fastest-rising white-space worth entering now.